A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Launched by ABBVIE · Mar 13, 2019

Keywords

ClinConnect Summary

This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of risankizumab 150 mg/mL formulation in PFS in adult participants with moderate to severe plaque psoriasis. The study included a 30-day screening period, a 28-week treatment period with study visits at Weeks 0, 4, 16 and 28, and a subsequent follow-up telephone call at approximately 20 weeks after the last dose of study drug. Study drug dosing consisted of 3 self-administered, subcutaneous (SC) doses on Weeks 0, 4, and 16. Dosing on Week 4 was self-adminis...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant has diagnosis of chronic plaque psoriasis for at least 6 months before the baseline visit.
• * Participant meets following disease activity criteria:
• • Stable moderate to severe chronic plaque psoriasis, defined as greater than or equal to 10% body surface area (BSA) psoriasis involvement, static physician global assessment (sPGA) score of greater than or equal to 3, and Psoriasis Area Severity Index (PASI) greater than or equal to 12 at Screening and baseline visit.
• • Candidate for systemic therapy as assessed by the investigator.
• Exclusion Criteria:
• • Participant has history of active skin disease other than psoriasis that could interfere with the assessment of psoriasis.
• • Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis.
• • Participant has previous exposure to risankizumab.